Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy

References

• Haberkorn U, Strauss LG, Reisser C, Haag D, Dimitrakop-oulou A, Ziegler S.. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: Relation of positron emission tomography to flow cytometry. J Nucl Med. 1991;32:1548–1555.
   PubMed Web of Science ®Google Scholar
• Minn H, Joensuu H, Ahonen A, Klemi P. Fluorooxyglucose imaging:A method to assess the proliferative activity of human cancer in vivo. Cancer. 1988;61:1776–1781.
   PubMed Web of Science ®Google Scholar
• Minn H, Clavo AC, Grénman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluoro-deoxyglucose and L-methionine in squamous cell carcinoma of the head and neck. J Nucl Med.7 1995;36:252–258.
   PubMed Web of Science ®Google Scholar
• Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer. 1988;61:1776–1781.
   PubMed Web of Science ®Google Scholar
• Jacob R, Welkoborsky HJ, Mann WJ, Jauch M, Amedee R. [Fluorine-18]fluorodeoxyglucose positron emission tomography,DNA ploidy and growth fraction in squamous-cell carcinomas of the head and neck. ORL J Otorhinolaryn-gol Relat Spec. 2001;63:307–313.
   PubMedGoogle Scholar
• Minn H, Maria Lapela M, Klemi PJ. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med. 2007;38:1907–1911.
   Google Scholar
• Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, El-Ghaziel A, Lehmann W, . Standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398–1404.
   PubMed Web of Science ®Google Scholar
• Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295–1300.
   PubMed Web of Science ®Google Scholar
• Roh JL, Pae KH, Choi SH, Kim JS, Lee S, Kim SB. 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced stage resectable squamous cell carcinoma of the larynx and hypopharynx. Eur J Surg Oncol. 2007;33:790–795.
   PubMedGoogle Scholar
• Lee SW, Nam SY, Im KC, Kim JS, Choi EK, Ahn SD. Prediction of prognosis using standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in nasopharyngeal carcinomas. Radiother Oncol. 2008;87:211–216.
   PubMed Web of Science ®Google Scholar
• Studer G, Lutolf UM, El-Bassiouni M, Rousson V, Glan-zmann C. Volumetric staging is superior to TNM and AJCC staging in predicting outcome of head and neck cancer treated with IMRT. Acta Oncologica. 2007; 46: 386–394.
   PubMed Web of Science ®Google Scholar
• Knegjens JL, Pameijer FA, Balm AJM. Tumor volume as outcome predictor in chemoradiation for advanced head and neck cancer [Abstract]. Int J Radiat Oncol Biol Phys. 2007;69(Suppl.1):S410–411.
   Google Scholar
• Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rübe C. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med. 2005;46:1342–1348.
   PubMed Web of Science ®Google Scholar
• Konski A, Doss M, Milestone B, Haluszka O, Hanlon A, Freedman G. The integration of 18- fluoro-deoxy-glu-cose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:1123–1128.
   PubMedGoogle Scholar
• Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA. Detection of interval distant metastases. Clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer. 2007;109:125–134.
   Google Scholar
• Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg1 2005;129:1232–1241.
   PubMed Web of Science ®Google Scholar
• Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JPA. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst. 2008;100(10):712–720.
   PubMedGoogle Scholar
• Borst GR, Belderbos JS, Boellaard R, Comans EF, De Jaeger K, Lammertsma AA. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer. 2005;41:1533–1541.
   PubMed Web of Science ®Google Scholar
• Eschmann SM, Friedel G, Paulsen F, . Is standardized (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging. 2006;33:263–269.
   PubMed Web of Science ®Google Scholar
• Kieninger AN, Welsh R, Bendick PJ, Zelenock G, Chmielewski GW. Positron-emission tomography as a prognostic tool for early-stage lung cancer. Am J Surg. 2006;191:433–436.
   PubMedGoogle Scholar
• Sasaki R, Komaki R, Macapinlac H, . [18F]fluorode-oxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23:1136–1143.
   PubMed Web of Science ®Google Scholar
• Pillot G, Siegel BA, Govindan R. Prognostic significance of fluorodeoxyglucose positron emission tomography in nonsmall cell lung cancer: a review. J Thorac Oncol. 2006;1:152–159.
   PubMed Web of Science ®Google Scholar
• Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295–1300.
   PubMed Web of Science ®Google Scholar
• Downey RJ, Akhurst T, Gonen M, Park B, Rusch V. Preop-erative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22:3255–3260.
   PubMed Web of Science ®Google Scholar
• Schwartz DL, Rajendran J, Yueh B, Coltrera MD, Leblanc M, Eary J. FDG-PET prediction of head and neck squamous cell cancer out-comes. Arch Otolaryngol Head Neck Surg. 2004;130:1361–1367.
   PubMedGoogle Scholar
• Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ. Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose–positron emission tomography scan in non–small-cell lung cancer: an analysis of 125 cases. J Clin Oncol. 1999;17:3201–3206.
   PubMed Web of Science ®Google Scholar
• Brun E, Kjellén E, Tennvall J, Ohlsson T, Sandell A, Perfekt R. FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127–135.
   PubMed Web of Science ®Google Scholar
• Kim SY, Roh JL, Kim MR, . Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med. 2007;48:752–757.
   PubMed Web of Science ®Google Scholar
• Greven KM, Williams DW 3rd, McGuirt WF Sr, Harkness BA, D’Agostino RB Jr, Keyes JW Jr. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck. 2001;23:942–946.
   PubMed Web of Science ®Google Scholar
• Vernon MR, Maheshwari M, Schultz CJ, Michel MA, Wong SJ, Campbell BH. Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:678–684.
   PubMed Web of Science ®Google Scholar
• Plataniotis GA, Theofanopoulou ME, Kalogera-Fountzila A, Haritanti A, Ciuleanou E. Prognostic impact of tumor volu-metry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial. Int J Radiat Oncol Biol Phys. 2004;59: 1018–1026.
   PubMedGoogle Scholar
• La TH, Filion EJ, Turnbull BB. Metabolic Tumor Volume Predicts for Recurrence and Death in Head-and-Neck Cancer. Int J Radiat Oncol Biol Phys. 2009.
   PubMedGoogle Scholar
• Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG. Metabolic tumor volume predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69:328–333.
   PubMed Web of Science ®Google Scholar
• Grow A, Quon A, Graves EE. Metabolic tumor volume as an independent prognostic factor in lymphoma. J Clin Oncol (ASCO Annual Meeting Proceedings Supplement) 2005;23:6594.
   Google Scholar
• Chatni SS, Thankappan K. Lymph node status cannot be ignored in survival analysis of laryngeal cancer. Arch Otolar-yngol Head Neck Surg. 2008 Jul;134(7):786
   PubMedGoogle Scholar
• Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys. 2002;53(2):353–359.
   PubMedGoogle Scholar